CHU de Limoges
CHU de Limoges
Limoges, France24 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis | Mast Cell Activation Disorders, Mastocytosis, Systemic, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, immune system disorder, indolent systemic mastocytosis, mastocytosis, neoplasm | Recruiting | Phase 2 / Phase 3 | 2026-10-07 | NCT04910685 | |
| A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis | Nutritional and Metabolic Diseases, amyloidosis, metabolic disease, proteostasis deficiencies | Active, not recruiting | Phase 2 | 2026-09-25 | NCT05250973 | |
| Efficacy of CAD in Screening Colonoscopy to Reduce the Risk of Advanced Adenoma at 3 Years. | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, intestinal polyp, neoplasm, polyp, rectal disorder | Recruiting | Not applicable | 2026-09-24 | NCT07299071 | |
| Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD) | Arterial Occlusive Diseases, Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Infarction, Male Urogenital Diseases, Necrosis, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, chronic renal failure syndrome, coronary artery disorder, diabetes mellitus, endocrine system disorder, glucose metabolism disease, heart disorder, ischemic disease, kidney disorder, kidney failure, metabolic disease, myocardial infarction, myocardial ischemia, peripheral arterial disease, peripheral vascular disease, urinary system disorder, vascular disorder | Recruiting | Phase 2 / Phase 3 | 2026-09-21 | NCT05485961 | |
| Subcutaneous Injection of Sodium Thiosulfate for Ectopic Calcifications or Ossifications. A Pilot Study | Ossification, Heterotopic, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, connective tissue disorder, dermatomyositis, muscle tissue disorder, musculoskeletal system disorder, myositis disease, nervous system disorder, neuromuscular disease, polymyositis, skin disorder, systemic sclerosis | Recruiting | Phase 2 | 2026-09-15 | NCT03582800 | |
| Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 3 | 2026-09-09 | NCT05633654 | |
| Impact of Annual Versus Biannual Infusions of Ocrelizumab in Patients With Active MS,After 2 Years of Initial Treatment, on Freedom From Radiological Disease Activity at Two Years: a Multicenter Randomized Controlled Non-inferiority Trial | CNS demyelinating autoimmune disease, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder | Active, not recruiting | Phase 3 | 2026-08-28 | NCT05999604 | |
| DESTINY Breast Respond HER2-(Ultra)Low Europe | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Not stated | 2026-08-19 | NCT05945732 | |
| PMCF Registry to Describe the Safety and Performance of p64, p48 MW and p64 MW in France | Aneurysm, brain aneurysm, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, intracranial arterial disease, nervous system disorder, vascular disorder | Recruiting | Not stated | 2026-08-05 | NCT07748572 | |
| Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2026-07-31 | NCT07106632 | |
| Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 2 | 2026-07-24 | NCT06078384 | |
| Onco-haematology Vigilance Card | Hematology; Medical Oncology; Molecular Targeted Therapies | Active, not recruiting | Not stated | 2026-06-26 | NCT04931329 | |
| Tolerance Study of Robotic-Assisted Virtual Reality Walking Rehabilitation for Non-Walking Stroke Patients | brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, nervous system disorder, stroke disorder, vascular disorder | Recruiting | Not applicable | 2026-06-25 | NCT06053619 | |
| IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 2 | 2026-06-17 | NCT05742607 | |
| Physical Activity Level at Home in CMT1A Patients: Wearable Sensor Assessment | Ambulation Difficulty, Charcot-Marie-Tooth Disease, Type IA, Charcot-Marie-Tooth disease, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Mobility Limitation, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, central nervous system malformation, hereditary disease, hereditary motor and sensory neuropathy, inherited neurodegenerative disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, peripheral nervous system disorder, polyneuropathy | Not yet recruiting | Not stated | 2026-05-22 | NCT07591779 | |
| Sacituzumab Govitecan in Primary HER2-negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 3 | 2026-04-22 | NCT04595565 | |
| Reliability of Minimally Trained Operator's Velocity-Time Integral Measurement Guided by Artificial Intelligence VTI | Critically Ill Patients; Tissue Hypoperfusion; Velocity-time Integral Measurement | Recruiting | Not applicable | 2026-04-21 | NCT06486467 | |
| Treatment Intensification With Temozolomide in Adults With a Glioblastoma | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), epithelial neoplasm, glioblastoma, glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Active, not recruiting | Phase 3 | 2026-03-30 | NCT03663725 | |
| Better Understand Motor Deficits Associated With Autism Spectrum Disorders: Development of an Assessment Protocol | Cognition Disorders, Cognitive Dysfunction, autism spectrum disorder, cognitive disorder, neurodevelopmental disorder, pervasive developmental disorder, psychiatric disorder | Recruiting | Not applicable | 2026-03-16 | NCT05236803 | |
| A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, epithelial neoplasm, glioma, neoplasm, neuroepithelial neoplasm, oligodendroglioma, primitive neuroectodermal tumor | Recruiting | Phase 3 | 2026-01-29 | NCT04702581 | |
| Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 2 | 2025-12-23 | NCT04965766 | |
| Evaluation of the Effectiveness of the Parkinson Specialized Teams Intervention | Parkinson disease, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, synucleinopathy | Recruiting | Not applicable | 2025-07-23 | NCT05433441 | |
| Clinical Relevance of Detecting Molecular Abnormalities in Glial Tumor Exosomes | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, epithelial neoplasm, glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Not applicable | 2024-12-13 | NCT06116903 | |
| A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, metastatic prostate carcinoma, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 3 | 2024-11-12 | NCT01957436 |